Hydrocortisone Milpharm (Hydrocortisone)

Hydrocortisone Milpharm is prescribed for conditions where cortisol replacement or anti‑inflammatory action is needed. It is commonly employed in clinical practice to manage endocrine insufficiency and various inflammatory or allergic disorders.

• Treatment of primary or secondary adrenal insufficiency (Addison’s disease).
• Management of acute adrenal crisis requiring rapid cortisol replacement.
• Control of inflammatory disorders such as ulcerative colitis or rheumatoid arthritis.
• Relief of moderate to severe allergic reactions, including skin and respiratory manifestations.
• Adjunct therapy for certain autoimmune conditions where immunosuppression is indicated.

• Hydrocortisone Milpharm acts as an agonist at intracellular glucocorticoid receptors. Binding triggers receptor translocation to the nucleus, where it modulates gene transcription. This up‑regulates anti‑inflammatory proteins (e.g., annexin‑1) and down‑regulates pro‑inflammatory cytokines such as interleukin‑1, interleukin‑6, and tumor necrosis factor‑α, thereby reducing inflammation and suppressing immune responses. The same receptor activation also replaces deficient endogenous cortisol systemically in adrenal insufficiency.

Adverse reactions to Hydrocortisone Milpharm can vary in frequency and severity; they are typically categorized as common or serious.

Common

• Increased appetite or weight gain.
• Fluid retention leading to mild edema.
• Elevated blood glucose levels, especially in diabetic patients.
• Gastrointestinal discomfort such as nausea or dyspepsia.

Serious

• Severe hypertension or cardiovascular complications.
• Opportunistic infections due to immunosuppression.
• Osteoporosis or pathological fractures with long‑term use.

Before initiating Hydrocortisone Milpharm, clinicians should evaluate several safety considerations to minimize risk.

• Assess for active infections; glucocorticoids can exacerbate bacterial, viral, or fungal growth.
• Review history of hypertension, diabetes, or cardiovascular disease, as the drug may worsen these conditions.
• Use the lowest effective dose for the shortest duration to reduce the likelihood of bone loss.
• Monitor electrolytes, especially sodium and potassium, because fluid balance may be altered.
• Caution in patients with peptic ulcer disease or gastrointestinal bleeding risk.
• Avoid abrupt discontinuation; taper gradually to prevent adrenal insufficiency.

Hydrocortisone Milpharm can affect the activity of other medicines; certain combinations should be avoided while others require careful monitoring.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone exposure.
• Simultaneous administration of high‑dose non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase the risk of gastrointestinal bleeding.

Use with caution

• Anticoagulants such as warfarin, because glucocorticoids may enhance anticoagulant effects.
• Vaccines, particularly live attenuated vaccines, due to possible diminished immune response.
• Diabetic medications, as hydrocortisone can raise blood glucose and may require dose adjustment.